Catalent announced a deal to acquire a clinical packaging facility in Minakuchi, located in the Shiga prefecture of Japan, from Teva-Takeda Pharmaceuticals, Nagoya Aichi, Japan.

Catalent today announced that Jean-François Chaubard, Senior Director, Open Innovation at Catalent Cell & Gene Therapy, will be presenting at the ISCT 2020 Paris Virtual conference.

Triphase Accelerator and Catalent today announced interim results for Triphase Accelerator’s multi-center, open-label, monotherapy study of TRPH-222 in heavily pre-treated patients with relapsed and/or refractory B-cell lymphoma.

Catalent today announced that it will present at the upcoming conference, ‘Outsourcing in Clinical Trials 2020 – A Virtual Experience’.

ABC News Nightline sat down with Catalent, and other manufacturing companies, to discuss their contributions to the fight against COVID-19.

Catalent today announced a collaboration with Ennaid Therapeutics to develop an oral, antiviral treatment targeted at COVID-19.

As a development and manufacturing partner that supplies medicines, clinical trial materials, and health products to patients and consumers, we are taking action to minimize the impact of the COVID-19 pandemic.

Catalent today welcomed the news by Humanigen, Inc., that it has dosed the first COVID-19 patient in its previously announced Phase 3 study for lenzilumab.

Arcturus and Catalent today announced a partnership to support the expected manufacture of Arcturus’ COVID-19 mRNA vaccine candidate, intended to protect against the SARS-CoV-2 coronavirus.